<DOC>
	<DOC>NCT02773316</DOC>
	<brief_summary>A study to assess bioavailability of a single dose of MR902 and to assess the effect of food on absorption</brief_summary>
	<brief_title>Study to Assess Pharmacokinetic (PK), Bioavailability &amp; Food Effect of MR902 Compared With Immediate Release (IR) Morphine Sulphate Oral Solution</brief_title>
	<detailed_description>Volunteers will receive a single dose of the investigational drug on 2 occasions and a reference drug on 1 occasion. Volunteers will be randomised to one of two groups, each group receiving a different dose strength of MR902 in fed and fasted state. The study involves a screening visit 21 days before first dosing and 3 overnight stays in 3 study periods, and a post-study medical visit. Volunteers will receive naltrexone to reduce anticipated opioid side effects.</detailed_description>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Morphine</mesh_term>
	<criteria>Healthy and free of significant abnormal findings as determined by medical history, physical examination, vital signs, laboratory tests and ECG. Body weight ranging from 55 to 100 kg and a BMI ≥ 18.5 and ≤ 30.0. Willing to eat all the food supplied throughout the study. The subject's primary care physician has confirmed within the last 12 months of first dosing that there is nothing in their medical history that would preclude their enrolment into a clinical study. Female subjects who are pregnant or lactating. Any history of drug or alcohol abuse, misuse, physical or psychological dependence. Any history of conditions that might interfere with drug absorption, distribution, metabolism or excretion. Use of opioid or opioid antagonistcontaining medication in the past 30 days. Any history of frequent nausea or vomiting regardless of etiology. Any history of seizures or symptomatic head trauma. History of respiratory depression, hypoxia or elevated carbon dioxide levels in the blood. History of paralytic ileus, gastrointestinal disease or other clinically significant gastrointestinal problems. Participation in a clinical drug study during the 90 days preceding the initial dose in this study. Any significant illness during the 4 weeks preceding entry into this study. Use of any medication including vitamins, herbal and/or mineral supplements during the 7 days preceding the initial dose or during the course of this study (with the exception of the continued use of HRT and contraceptives). History of smoking within 60 days of IMP administration and refusal to abstain from smoking during the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>